Obesity has increased dramatically over the past 30 years in the US and is associated with increased mortality rates of various cancers, including prostate cancer (PCa). Insights into the mechanism(s) underiying the enhanced progression of PCa associated with obesity are urgently needed to develop new strategies for preventing and treating obesity related PCa. Recently, we have reported that obesity has a significant role in PCa progression for patients with localized disease independent of treatment (prostatectomy or radiation. Body mass index (BMI) appears to be an independent risk factor for either biochemical failure (BF) or clinical failure (CF) and our new data suggest that fat intake modulates tumor progression. In animal studies, we have recently found that positive (obese diet) and negative (calorie- restricted diet) energy balance modulate activity of the Akt/mTOR signaling pathway in several mouse tissues including the prostate. Finally, preliminary studies have shown enhanced progression of PCa in HiMyc transgenic mice maintained on an obesity-inducing high fat diet. Our data also suggest that enhanced signaling through Akt and mTOR may play a role in this enhanced progression associated with maintenance on an obesity-inducing diet. Taken together, these findings suggest that pathways activated by obesity, such as the Akt/mTOR pathways, may be key targets for preventing and controlling obesity-related PCa progression. In this project, we propose to use the well-characterized HiMyc mouse prostate tumor model, in combination with dietary and pharmacologic approaches, to test this hypothesis. Additionally, we will evaluate the relevance of changes in these signaling pathways (including both upstream and downstream components) using serum, germline DNA and tumor tissue from PCa patients who are part of ongoing studies at the UT MD Anderson Cancer Center. Findings from these proposed studies will provide the basis for future translational studies targeting specific pathways via lifestyle and pharmacologic approaches to reduce PCa specific mortality. The hypothesis to be tested in this proposal is that diet-induced obesity and/or high fat diet impacts PCa progression through modulation of Akt, mTOR and their downstream signaling pathways.
The specific aims are 1) To establish the impact and underiying mechanisms of enhanced PCa progression in HiMyc mice due to diet-induced obesity, 2) To characterize pharmacologic interventions that offset the increased risk of PCa progression associated with diet-induced obesity (DIO)/ high fat (HF) diet in HiMyc mice, and 3) To extend the dietary and intervention associations with PCa progression identified in Specific Aims 1 and 2 to two well-characterized populations of PCa patients.

Public Health Relevance

(See Instructions): In this project, we propose to use the well-characterized HiMyc mouse prostate tumor model, in combination with dietary and pharmacologic approaches, to test the hypothesis that diet-induced obesity and/or high fat diet impacts PCa progression through modulation of Akt, mTOR and their downstream signaling pathways. Additionally, we will evaluate the relevance of changes in these signaling pathways (including both upstream and downstream components) using serum, germline DNA and tumor tissue from PCa patients who are part of ongoing studies at the UT MD Anderson Cancer Center. Findings from these proposed studies will provide the basis for future translational studies targeting specific pathways via lifestyle and pharmacologic approaches to reduce PCa specific mortality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140388-04
Application #
8380583
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
4
Fiscal Year
2012
Total Cost
$234,485
Indirect Cost
$81,251
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2017) Enzalutamide and CXCR7 inhibitor Combination Treatment Suppresses Cell Growth and Angiogenic Signaling in Castration-Resistant Prostate Cancer Models. Int J Cancer :
Lin, Song-Chang; Lee, Yu-Chen; Yu, Guoyu et al. (2017) Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell 41:467-480.e3
Gao, Jianjun; Ward, John F; Pettaway, Curtis A et al. (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23:551-555
Yu, Kai-Jie; Li, Jeffrey K; Lee, Yu-Chen et al. (2017) Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone. Oncotarget 8:74987-75006
Tu, Huakang; Gu, Jian; Meng, Qing H et al. (2017) Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett 13:1949-1957
Gökce, Mehmet I; Wang, Xuemei; Frost, Jacqueline et al. (2017) Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer 123:583-591
Karanika, Styliani; Karantanos, Theodoros; Li, Likun et al. (2017) Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18:1970-1981
Saha, Achinto; Blando, Jorge; Fernandez, Irina et al. (2016) Linneg Sca-1high CD49fhigh prostate cancer cells derived from the Hi-Myc mouse model are tumor-initiating cells with basal-epithelial characteristics and differentiation potential in vitro and in vivo. Oncotarget 7:25194-207
Fong, Eliza L S; Wan, Xinhai; Yang, Jun et al. (2016) A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials 77:164-72
Subudhi, Sumit K; Aparicio, Ana; Gao, Jianjun et al. (2016) Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113:11919-11924

Showing the most recent 10 out of 198 publications